Clinical trials: Sexual Risk
Pre-exposure Prophylaxis, HIV Infections
Project Phakama: Testing Support Strategies to Empower Young Women on PrEP in South Africa
The goal of this trial is to understand which strategies work best to support pre-exposure prophylaxis (PrEP) use among female sex workers (FSW) and adolescent girls and youth women (AGYW) in uMgungundlovu, KwaZulu-Natal, South…
- Trial name
- NCT06274060
- Testing
- Case management, Food vouchers, PrEP support buddy
- Where
- South Africa
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV/AIDS
Using Open Contest and Neuro-influence Experiment to Develop and Evaluate PrEP Promotion Messages for High Risk Men
The aim of this study is to examine the utility of neuroimaging technique to evaluate pre-exposure prophylaxis (PrEP) promotion messages for men who have sex with men (MSM) at risk of HIV in Baltimore.
- Trial name
- NCT04166851
- Testing
- PrEP campaign messages developed via open contest, PrEP campaign messages developed via social marketing approach
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Control arm_Bolstered Care, Treatment arm_HIVRR+S+FL
Kyaterekera Project: A Combination Intervention Addressing Sexual Risk-Taking Behaviors Among Vulnerable Women in Uganda
Guided by Social Cognitive and Asset theories as well as Behavioral Economics (BE) principles,the proposed RCT is carefully designed to test the additive contributions of savings-led microfinance beyond traditional HIV risk…
- Conditions
- Control arm_Bolstered Care, Treatment arm_HIVRR+S+FL, Treatment arm_HIVRR+S+FL+M
- Trial name
- NCT03583541
- Testing
- HIV Risk Reduction, Financial Literacy, Mentorship
- Where
- Uganda
- Volunteers
- 542 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Cardiovascular Diseases, Hepatitis C
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls.
- Conditions
- Cardiovascular Diseases, Hepatitis C, Hiv
- Trial name
- CHROME (NCT03823911)
- Testing
- Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
- Where
- 2 sites in United States
- Volunteers
- 87 people
- Sponsor
- University of Maryland, Baltimore
HIV Infections, Heart Disease
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the HIV+ population.
- Trial name
- NCT01218802
- Testing
- Rosuvastatin 10 mg. daily for 96 weeks
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University Hospitals Cleveland Medical Center
HIV
The Health Check-Up for Expectant Moms
The objective of this study is to develop and determine feasibility of a computer-delivered intervention (Health Check-up for Expectant Moms) approach to target women at risk for HIV or other sexually transmitted infections…
- Trial name
- NCT02120716
- Testing
- Health Check-Up for Expectant Moms
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Butler Hospital
Acquired Immune Deficiency Syndrome Virus, Hepatitis C
Brief Intervention for Rural Women at High Risk for HIV/HCV
The overall aim of this study is to reduce risk behaviors and increase health and behavioral health service utilization among disadvantaged, drug-using rural women at high risk for HIV and HCV.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Hepatitis C, Drug Abuse
- Trial name
- WISH (NCT01840722)
- Testing
- MI-based HIV Risk Reduction
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Michele Staton
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth…
- Trial name
- PURPOSE 2 (NCT04925752)
- Testing
- Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN)
- Where
- 93 sites in United States, Argentina and 6 more
- Volunteers
- 3,292 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences